Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trialListen(1 min)Listen(1 min)Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.The companies said a Phase 3 study of its Lyme disease vaccine candidate demonstrated more than 70% efficacy in preventing Lyme disease in those 5 and older. However, the predetermined statistical criterion was not met in the primary endpoint.About the AuthorSteven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage. Follow Steve on Twitter: @MKTWgoldstein.A Dow Jones CompanyCopyright © 2026 MarketWatch, Inc. All rights reserved.